Clinical Research Findings on AOD-9604 In clinical trials involving approximately 900 participants across six human studies, AOD-9604 demonstrated a favorable safety and tolerability profile
Br J Dermatol 2006;155(1):39-49
Therefore, it is crucial for researchers to stay up-to-date on the literature to ensure accurate and safe administration of DSIP in their studies
EXAMPLE 13: CONFIRMATION ON THE EFFECT OF TONICITY AGENT TYPE IN THE HISTIDINE-BUFFERED FORMULATION AND THE EFFECT OF THE CITRATE- BUFFERED FORMULATION ON THE SUBCUTANEOUS TOLERANCE UPON SUBCUTANEOUS INJECTION This experiment examines: (1) the effect that the type of tonicity agent has on the local tolerance profile, upon subcutaneous injection, of an otherwise identical, histidine-buffered co-formulation
It helps to connect people interested in research studies with researchers from top medical centers across the U.S
The compound's peptidomimetic structure resists degradation by gastrointestinal and serum proteases, allowing oral dosing to achieve effective CNS concentrations